Prostate cancer; reaction to covid vaccine large boils on back and neck requiting lancing; Patient received 3rd dose of mRNA-1273 vaccine 9 months from primary series/Patient took 1st dose on 22-JAN-2021,2nd Dose on 24-FEB-2021 & 3rd dose on 21-NOV-2021; This spontaneous case was reported by a consumer and describes the occurrence of PROSTATE CANCER (Prostate cancer) and FURUNCLE (reaction to covid vaccine large boils on back and neck requiting lancing) in an elderly male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) solution for injection for Rheumatoid arthritis.    No Medical History information was reported.   On 22-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 21-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate free. On an unknown date, the patient experienced PROSTATE CANCER (Prostate cancer) (seriousness criterion medically significant), FURUNCLE (reaction to covid vaccine large boils on back and neck requiting lancing) (seriousness criterion medically significant) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received 3rd dose of mRNA-1273 vaccine 9 months from primary series/Patient took 1st dose on 22-JAN-2021,2nd Dose on 24-FEB-2021 & 3rd dose on 21-NOV-2021). At the time of the report, PROSTATE CANCER (Prostate cancer) was resolving, FURUNCLE (reaction to covid vaccine large boils on back and neck requiting lancing) had resolved and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received 3rd dose of mRNA-1273 vaccine 9 months from primary series/Patient took 1st dose on 22-JAN-2021,2nd Dose on 24-FEB-2021 & 3rd dose on 21-NOV-2021) outcome was unknown.            Concomitant medication was not reported.  On unknown dates, the patient experienced prostate cancer and reaction to covid vaccine large boils on back and neck requiting lancing. On an unknown date, reaction to covid vaccine large boils on back and neck requiting lancing resolved. Moderna COVID-19 vaccine (elasomeran) was also considered suspect.   The patient had Prostate cancer diagnosed with radiation treatment and had reaction to Covid vaccine at the end of his second shot. Large boils on back and neck requiting lancing. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  Treatment medication was not reported.   This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.  Comment company: This spontaneous case concerns an elderly male patient of an unknown age, with no reported medical history, who experienced the unexpected serious (medically significant) events of Prostate cancer and Furuncle that occurred on an unknown date after receiving the mRNA-1273 vaccine. It was reported that patient was diagnosed with prostate cancer and had radiation therapy and had large boils on the back and neck after the 2nd dose. Patient received primary series of mRNA-1273 vaccine 33 days apart, and 3rd dose was given approximately 9 months later. Clinical course and treatment details were not reported. On an unknown date, co-suspect Adalimumab was given for rheumatoid arthritis which could be a confounder. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case concerns an elderly male patient of an unknown age, with no reported medical history, who experienced the unexpected serious (medically significant) events of Prostate cancer and Furuncle that occurred on an unknown date after receiving the mRNA-1273 vaccine. It was reported that patient was diagnosed with prostate cancer and had radiation therapy and had large boils on the back and neck after the 2nd dose. Patient received primary series of mRNA-1273 vaccine 33 days apart, and 3rd dose was given approximately 9 months later. Clinical course and treatment details were not reported. On an unknown date, co-suspect Adalimumab was given for rheumatoid arthritis which could be a confounder. The benefit-risk relationship of mRNA-1273 is not affected by this report.